Last reviewed · How we verify
HB-201 intravenous administration.
At a glance
| Generic name | HB-201 intravenous administration. |
|---|---|
| Sponsor | Hookipa Biotech GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (PHASE1, PHASE2)
- A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer (EARLY_PHASE1)
- A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB-201 intravenous administration. CI brief — competitive landscape report
- HB-201 intravenous administration. updates RSS · CI watch RSS
- Hookipa Biotech GmbH portfolio CI